The universal rise in incidence of pediatric diabetes (ranging from 5 to 40 cases per 100 000 per year) has been paralleled by increasing recognition of post-transplant hyperglycemia as a unique form of iatrogenic diabetes. PTDM is an increasingly recognized complication of solid organ transplantation (1-3). Overall reported frequencies of PTDM in adults range from 4% to 40% (4), depending on the transplanted organ, definition of diabetes, and immunosuppressive regimen (5). Risk factors for PTDM include tacrolimus use (6), age at transplant, obesity, family history of diabetes, pre-and post-transplant GI, ethnicity, and occasionally HLA sub-types (7). The long-term implications of pediatric PTDM, in terms of acceleration of known diabetic complications or development of new ones following decades of immune suppression remain to be discovered (8). Despite observed associations of PTDM with use of glucocorticoids (prednisone), tacrolimus (FK506), and less commonly, with cyclosporine (9), the relation of PTDM to various immunosuppressive medications has not been fully elucidated in the pediatric liver transplant population. The objectives of this study were to determine the frequency and characteristics of GI and PTDM in a large cohort of pediatric liver-transplant recipients. Abstract: To determine the characteristics of pediatric liver transplant recipients who develop GI and/or PTDM, data on children undergoing their first liver transplant from the SPLIT database were analyzed (n = 1611). Recipient and donor characteristics that were evaluated included age at transplant, gender, race, primary disease, hospitalization status at transplant, BMI, recipient and donor CMV status, donor type, donor age, and primary immunosuppression. GI/PTDM was found in 214 individuals (13%) of whom 166 (78%) were diagnosed within 30 days of transplantation (early GI/PTDM). Multivariate analyses suggests that age >5 yr at transplant, hospitalization at transplant, a primary diagnosis other than BA, early steroid use, and tacrolimus use are associated with increased incidence of early GI. Routine monitoring for the development of GI and post-transplant diabetes is indicated in the short-and long-term care of children after liver transplantation.
The universal rise in incidence of pediatric diabetes (ranging from 5 to 40 cases per 100 000 per year) has been paralleled by increasing recognition of post-transplant hyperglycemia as a unique form of iatrogenic diabetes. PTDM is an increasingly recognized complication of solid organ transplantation (1) (2) (3) . Overall reported frequencies of PTDM in adults range from 4% to 40% (4), depending on the transplanted organ, definition of diabetes, and immunosuppressive regimen (5) . Risk factors for PTDM include tacrolimus use (6) , age at transplant, obesity, family history of diabetes, pre-and post-transplant GI, ethnicity, and occasionally HLA sub-types (7) . The long-term implications of pediatric PTDM, in terms of acceleration of known diabetic complications or development of new ones following decades of immune suppression remain to be discovered (8) . Despite observed associations of PTDM with use of glucocorticoids (prednisone), tacrolimus (FK506), and less commonly, with cyclosporine (9), the relation of PTDM to various immunosuppressive medications has not been fully elucidated in the pediatric liver transplant population. The objectives of this study were to determine the frequency and characteristics of GI and PTDM in a large cohort of pediatric liver-transplant recipients.
Materials and methods
The SPLIT database (10) is a prospective self-initiated center-reporting registry which was started in 1995 and now includes data from 3161 patients at 44 centers in the USA and Canada. The number of patients per center ranges from two to 283. This outcome analysis was based on data reported up to June of 2004 from 1611 patients who received their first liver only transplant while registered in one of the 39 participating SPLIT centers at the time of this analysis. Post-transplant follow-up forms are completed at 30 days, 6, 12, and 18 months and then annually following transplantation. Follow-up forms query use of insulin, other antihyperglycemic drugs or other evidence of diabetes or GI at any time point since the last follow-up. Plasma fasting glucose levels were not requested as part of the data collection and non-fasting blood glucose levels were inconsistently reported. Data regarding pre-existing diabetes prior to transplant were not collected. Therefore, for this analysis, patients were categorized as having GI or PTDM if they received insulin, antihyperglycemic drugs or were termed by their primary center as having diabetes or GI at any time point during post-transplant follow-up. Patients reported to have GI and or PTDM in the first 30 days post-transplant were considered to have developed early GI (PTDM). Data on diabetes-specific start or end dates were not collected to enable accurate estimation of diabetes duration. The study visit date at which GI/PTDM was first reported was used as the start date and end date was the last consecutive visit date at which diabetes was reported. The diabetes duration was set to 0 days when diabetes was not reported for more than one visit.
Patient and donor factors that were evaluated included age at transplant, gender, race, primary disease, hospitalization status at transplant, BMI at transplant, patient and donor CMV status, donor type, donor age, primary immunosuppression, steroid use, use of monoclonal and polyclonal antibodies, and year of transplant.
FisherÕs Exact and chi-squared tests were used in the univariate analyses. Mulitvariate logistic regression analyses with backward elimination method was used to develop a risk factors model for early GI/PTDM. Table 1 provides a summary of patient characteristics at the time of transplant. One-third of the patients were <1 yr of age at the time of transplant and 34.7% were >5 yr of age at transplant. The median age at transplant is 1.93 yr. Forty-two percent of the patients were diagnosed with BA and fulminant liver failure patients accounted for 14.2% of the cohort. More than half of the patients (56.7%) were not hospitalized at time of transplant. The standardized height was below age and gender adjusted mean for 80% of the patients and >2 s.d. below mean for more than a quarter of the patients. Unlike adults, BMI is age and gender specific for children. Normative data on BMI is available from CDC for children and young adults between the ages of 2 and 20 yr. CDC defines children with age and gender adjusted BMI in top 5% as being overweight and between 85th Table 2 describes early and late GI/PTDM event rates by patient characteristics at transplant. Of the 1611 patients receiving their first liver-only transplant, 214 (13.3%) developed GI/ PTDM. The majority of patients developed GI/ PTDM within one month following transplantation (166/214, 77.6%). At subsequent follow-up visits, the number of children with a first report of GI/PTDM decreased sharply: 30 at month 6; five at month 12; four at month 18; four at month 24; two at month 36; two at month 48; and one at month 72. The mean duration of GI/ PTDM for children diagnosed at one and six months (n = 196) was 74.8 and 80.4 days, respectively.
Results
As a result of staggered entry of patients in to the study leading to unequal follow-up posttransplant, all statistical comparisons focus on the development of GI/PTDM in the first month post-transplant (termed as early GI/PTDM). Overall, 10.3% of patients developed early GI/ PTDM. Children >5 yr of age were more likely to develop early GI/PTDM (8.1% for age <1 yr, 7.6% age 1-4 yr, 12.0% age 5-12 yr and 19.1% age >12 yr; p-value < 0.0001). Children of black or Hispanic race were more likely to develop early GI/PTDM compared to whites (11.1% black, 15.6% Hispanic, and 8.9% white; p-value 0.0252). Children diagnosed with BA had the lowest incidence of early GI/PTDM (6.7%). This is consistent with the observation that children <5 yr of age at transplant had lower incidence of early GI/PTDM. It was interesting to note that there was no era effect on the development of early GI/PTDM (10.8% before year 2000 and 9.8% between 2000 and 2004). Table 3 describes the impact of clinical factors at transplant on the development of early GI/ PTDM. Sixteen percent of the children in ICU at transplant developed early GI/PTDM compared to 10.1% of those hospitalized at transplant and 7.9% for those non-hospitalized (p-value < 0.0001). CMV negative patients had lower incidence of early GI/PTDM (9.1%) compared to patients that were CMV positive at transplant (12.5%; p-value = 0.0326). The incidence of early GI/PTDM in children receiving a graft from a live donor is less than half of those receiving a cadaveric graft (5.6% vs. 11.3%, respectively; p-value = 0.0066). Donor age and CMV status were not significant predictors of GI/PTDM in the univariate analyses. For children >2 yr of age the incidence of early GI/PTDM did not vary by standardized BMI score at the time of transplant. Table 4 shows the incidence of early PTDM in BA patients. The data suggest that the incidence of early PTDM is higher among BA patients that were >5 yr of age at transplant (9.8% vs. 6.3%), but the differences are not statistically significant. The majority of BA patients are <5 yr of age, however, the results of the multivariate analyses show that age is a significant predictor of diabetes after adjusting for other predictors including the primary diagnosis. Tables 5 and 6 summarize the influence of primary immunosuppression on the development of early GI/PTDM. Fifty-eight percent of patients were placed on tacrolimus therapy and 26.9% received cyclosporine. Children placed on tacrolimus therapy have a higher incidence of early GI/PTDM (14.2%) compared to those taking cyclosporine (5.5%; p-value < 0.0001). More than 90% of children were initially given steroids. Eleven percent of these children developed early GI/PTDM compared to only 2.0% of children not using steroids at transplant (p-value = 0.0019). The use of induction therapy at transplant did not have an impact on the development of GI/PTDM in this analysis.
Factors significant at 0.15 level in the univariate analyses were added to the initial multivariate model to identify risk factor for the development of early GI/PTDM. The final multivariate model presented in Table 7 shows that children <5 yr of age at transplant, not hospitalized, and diagnosed with BA are protected against the development of early GI/PTDM. 
Discussion
In this study, we found that GI/PTDM occurred in approximately 13% of patients who received a liver transplant. This incidence was similar to the incidence of PTDM in other solid organ transplants in children (5). More than three-quarters of the children developed GI/PTDM within one month of transplant, but the mean duration of GI/PTDM in this cohort was relatively short -74 days suggesting that diabetes in this analysis is a transient phenomenon. Only a few children developed GI/PTDM at one or >1 yr after transplant, but the reported duration was longer.
The results of the multivariate analysis showed that early GI/PTDM in pediatric liver transplant recipients is associated with older age, diagnosis other than BA, and the use of tacrolimus and steroids. The diabetogenic effect of several commonly used immunosuppressive drugs is well known and our results support several other reports including those in which steroids and/or tacrolimus were used as primary immune suppressants (4-6). In our study, steroid predominance at the outset, and tacrolimus use in the majority, might have contributed to the observed incidence of GI/PTDM. The odds ratios for both these therapies suggest a similar strength of association with PTDM. This contrasts with a much lesser frequency of PTDM in heart transplant recipients when placed on a steroid-sparing cyclosporinebased regimen (11) . Dose effects, particularly cumulative steroid exposure, could not be analyzed within the context of this study, but are important aspects to consider in future prospective analyses. Separating the independent role of steroids in the development of GI/PTDM is an important objective as new treatment initiatives in pediatric transplantation suggest that steroidfree regimens do not compromise graft function or survival.
The significant association of both tacrolimus and steroids with early GI/PTDM support two important clinical strategies. First, reducing corticosteroid exposure could decrease, but probably not eliminate PTDM in this population. Secondly, in children who develop GI/PTDM, consideration should be given to decreasing or stopping steroids. If hyperglycemia is difficult to control with standard insulin dosages, substituting cyclosporine, mycophenolate mofetil, or sirolimus should be considered if graft function is stable.
The other significant risk factors for early GI/ PTDM identified in multivariate analysis were recipient age >5 yr and a primary diagnosis other than BA. A protective effect of BA, independent of age and BMI at transplant is not easily explained, and may just be a random association or be related to other patient covariates. The incidence of diabetes in children with BA who did not receive a liver transplant is not clearly identified in the current literature. As the pathogenesis of BA is still unknown, the importance of the association we have shown remains to be elucidated. Protection against diabetes in patients with BA may be related to disease-specific diabetes resistant HLA subtypes and cytokine gene polymorphisms (12) . The independent effect of age >5 yr may be related to the known increased incidence of insulin-resistant (type 2) diabetes with age in all children. High BMI is a well-described risk factor for the development of this type of diabetes in children (13) . The lack of correlation with BMI in this study is likely because we only assessed BMI at transplant as a risk factor for developing early GI/ PTDM. Future longitudinal studies are needed to understand the effect of BMI on the development of PTDM during long-term follow up.
An inherent caveat to this analysis, is the discrepancy between the definition of diabetes in the SPLIT database at the time of the study, and the standard definition by the ADA (14) . Although the latter definition of a fasting blood glucose in excess of 124 mg/dL or a post-prandial level exceeding 200 mg/dL may not have been consistently used by participating centers, children were primarily classified as diabetic based on their need for insulin or other antihyperglycemic drugs. It is assumed that most clinicians considered this definition in their decision to initiate insulin or other anti-hyperglycemic therapy. The definition of diabetes used for this study likely excluded children with undiagnosed or untreated diabetes and those who would be considered prediabetic and thus underestimated true incidence. Screening for PTDM has become more rigorous at pediatric transplant centers within the recent past and the current follow-up data collection for the SPLIT registry includes fasting glucose values on all children age five yr and older. This more careful investigation may reveal an even larger population of children that are classified as diabetic using the ADA definition.
Another limitation of this analysis is that it is based on a large multi-center database in which long-term follow-up data may not be available, or consistently collected on patients from various centers. Long-term follow-up regarding compliance with the immunosuppressive regimen and annual blood glucose testing may similarly be incomplete, compromising the accuracy of the above results. These effects would be expected to further contribute to an underestimation of the true incidence. Patients with no follow-up may have diabetes which does not come to medical attention, and patients that die early in their post-transplant course may have developed diabetes with prolonged exposure to immunosuppressive medications. A comprehensive, prospective screening program that incorporates ADA guidelines and definitions will be necessary to more confidently estimate the risk of PTDM.
The mechanism of pediatric post-transplant diabetes is likely to be a composite scenario of both insulin deficiency and insulin resistance. This pertains to both conventional steroid-based regimens, as well as more experimental steroidfree protocols that may include other immunosuppressants, such as sirolimus, polyclonal, or monoclonal antibody preparations. Steroids are known antagonists of insulin action (11) . Sirolimus has opposing effects on islet function dependent on the dose (15) . The mechanism by which tacrolimus may lead to diabetes is a complex one, where islet cell-specific autoimmunity, insulinopenia and insulin resistance have been suggested (16) . We do not know, if the known diabetogenic effects of calcineurin inhibitors and steroids are independent, additive, or synergistic. Considering that immune suppression in this vulnerable (pediatric) age group may span several decades, there is concern over chronic effects on micro-and macrovascular systems that warrants more comprehensive short-and long-term monitoring.
To further understand the pathogenesis of posttransplant diabetes (17) , future studies should include testing for endogenous insulin production and insulin resistance by measuring plasma glucose and C-peptide (the connecting peptide of the two endogenous insulin chains). In this study, the pathogenesis of PTDM is limited by the lack of comprehensive pretransplant glucose tolerance evaluation, especially as insulin-resistant diabetes is asymptomatic in approximately 50% of patients (18) . Improved pretransplant screening for GI is indicated. Glycemic, autoimmune, and HLA characteristics of children and adolescents developing PTDM and determinants of oral antihyperglycemic drugs vs. insulin therapy remain to be described prospectively. A better understanding of the pathogenesis of PTDM may allow for the development of a predictive index for pediatric PTDM which could have a pivotal impact on immune suppression selection. This, in turn, may highly enhance the duration and quality of life in liver transplant recipient children.
